RLReto Lang

Reto Lang

*This is an algorithmically generated author record based on publicly available information.

Reto Lang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Photoswitchable RNA Degraders for Spatiotemporal Activation of Host-Directed Antivirals in Mammalian Cells

    by Moritz Fink, Susanne Wolfrum, Reto Lang, Volker Thiel, Erick M. Carreira

    Strategies to develop broad-spectrum antivirals are highly sought after. A promising modern approach includes recruitment of host proteins as a means of activating immune responses that target multiple virus families. Host-directed therapies require a balance of antiviral effects and immunopathology. Herein, a known RNase L ligand was retrofitted with a hemithioindigo photoswitch to obtain a novel light-activatable pyrazol-hemithioindigo pharmacophore. This newly developed class of RNase L ligands allows spatiotemporal control of RNA degradation with isolated enzyme as well as in human cancer cells and virus infected cells. This work showcases the implementation of photopharmacology to elicit antiviral effects as potential strategy to limit off-site toxicity stemming from RNA degradation. The designed photoswitches provide a tool to study exogenous, conditional activation of RNase L for the development of broad-spectrum antivirals.


  • Open Access

    An RNA replicon system to investigate promising inhibitors of feline coronavirus

    by Kimberly Schmied, Rosina Ehmann, Claudia Kristen-Burmann, Nadine Ebert, Güliz Tuba Barut, Lea Almeida, Jenna N. Kelly, Lisa Thomann, Hanspeter Stalder, Reto Lang, et al.

    FIPV is of great significance in the cat population around the world, causing 0.3%–1.4% of feline deaths in veterinary practices (2). As there are neither effective preventive measures nor approved treatment options available, there is an urgent need to identify antiviral drugs against FIPV. Our FCoV replicon system provides a valuable tool for drug discovery in vitro . Due to the lack of cell culture systems for serotype I FCoVs (the serotype most prevalent in the feline population) (2), a different system is needed to study these viruses. A viral replicon system is a valuable tool for studying FCoVs. Overall, our results demonstrate the utility of the serotype I feline coronavirus replicon system for antiviral screening as well as to study this virus in general. We propose several compounds representing promising candidates for future clinical trials and ultimately with the potential to save cats suffering from FIP.


  • Top Cited Papers

    SARS-CoV-2 biology and host interactions

    by Silvio Steiner, Annika Kratzel, G. Tuba Barut, Reto M. Lang, Etori Aguiar Moreira, Lisa Thomann, Jenna N. Kelly, Volker Thiel

    The zoonotic emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the ensuing coronavirus disease 2019 (COVID-19) pandemic have profoundly affected our society. The rapid spread and continuous evolution of new SARS-CoV-2 variants continue to threaten global public health. Recent scientific advances have dissected many of the molecular and cellular mechanisms involved in coronavirus infections, and large-scale screens have uncovered novel host-cell factors that are vitally important for the virus life cycle. In this Review, we provide an updated summary of the SARS-CoV-2 life cycle, gene function and virus–host interactions, including recent landmark findings on general aspects of coronavirus biology and newly discovered host factors necessary for virus replication.